Markets:

Overview

News

Currencies

International

Treasuries

GH Research PLC - Ordinary Shares (NQ:GHRS)

30.57 -0.07 (-0.24%)

Streaming Delayed Price Updated: 10:31 AM EDT, Aug 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GH Research PLC - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting

May 15, 2025

From GH Research PLC

Via GlobeNewswire

GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates

May 08, 2025

From GH Research PLC

Via GlobeNewswire

JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

March 20, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

March 20, 2025

Via Benzinga

GH Research Reports Full Year 2024 Financial Results and Provides Business Updates

February 27, 2025

From GH Research PLC

Via GlobeNewswire

These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week ↗

February 10, 2025

These five small-cap pharma and biotech stocks drew heavy attention on Stocktwits last week, driven by key trial results, FDA updates, and promising drug developments.

Via Stocktwits

On Thursday, there are stocks with unusual volume. Let's take a look. ↗

February 06, 2025

Let's explore the current happenings on the US markets on Thursday. Below, you'll find the stocks exhibiting unusual volume in today's session.

Via Chartmill

These stocks have an unusual volume in today's session ↗

February 05, 2025

Discover the stocks with unexpected trading volume in today's session on the US markets.

Via Chartmill

GH Research Announces Pricing of $150 Million Public Offering

February 04, 2025

From GH Research PLC

Via GlobeNewswire

Unusual volume stocks in Tuesday's session ↗

February 04, 2025

In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.

Via Chartmill

GH Research Announces Proposed Public Offering

February 03, 2025

From GH Research PLC

Via GlobeNewswire

Crude Oil Moves Higher; Owens & Minor Shares Plummet ↗

February 03, 2025

Via Benzinga

Dow Falls 150 Points; ISM Manufacturing PMI Rises In January ↗

February 03, 2025

Via Benzinga

Topics Stocks

IDEXX Laboratories Posts Upbeat Results, Joins Stratasys, Saia And Other Big Stocks Moving Higher On Monday ↗

February 03, 2025

Via Benzinga

Why Is GH Research Stock Trading Higher On Monday? ↗

February 03, 2025

GH Research's Phase 2b trial of GH001 for treatment-resistant depression met its primary endpoint, showing significant efficacy and a favorable safety profile.

Via Benzinga

S&P 500 Down Over 1%; Tyson Foods Posts Upbeat Results ↗

February 03, 2025

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

February 03, 2025

Via Benzinga

GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction

February 03, 2025

From GH Research PLC

Via GlobeNewswire

Why Triumph Group Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket ↗

February 03, 2025

Via Benzinga

GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

January 31, 2025

From GH Research PLC

Via GlobeNewswire

Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

January 22, 2025

Via Benzinga

GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents

January 10, 2025

From GH Research PLC

Via GlobeNewswire

GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates

November 14, 2024

From GH Research PLC

Via GlobeNewswire

3 Fast-Growing Stocks Analysts See Doubling in Price

November 11, 2024

Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches.

Via MarketBeat

Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week ↗

September 15, 2024

The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come.

Via Talk Markets

Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th ↗

September 10, 2024

While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are...

Via Talk Markets

Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August ↗

September 06, 2024

The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a...

Via Talk Markets

Irish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug Trials ↗

September 05, 2024

Irish psychedelic biotech firm GH Research PLC (NASDAQ: GHRS) reported on Tuesday financial results for the second quarter ended June 30, 2024. Cash, cash equivalents, other financial assets and...

Via Benzinga

GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates

September 03, 2024

From GH Research PLC

Via GlobeNewswire

GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer

September 03, 2024

From GH Research PLC

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.